Novel compounds with antiproliferative activity against imatinib-resistant cell lines

Molecular Cancer Therapeutics

Volumn 6, Issue 2, 2007, Pages 655-666

  Lerma, Enrica I ^a   Nguyen, Viet Anh ^b   Wang, Tao ^b   Tipping, Alex ^c   Melo, Junia V ^c   Kufe, Donald ^d   Austin, David J ^b   Deisseroth, Albert ^a  

^a SIDNEY KIMMEL CANCER CENTER   (United States)

^b YALE UNIVERSITY   (United States)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

^d DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLENE DERIVATIVE; ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; FURAN DERIVATIVE; IMATINIB; STU 571; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL ASSAY; CELL GROWTH; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYCLOADDITION; DRUG DETERMINATION; DRUG SCREENING; ENZYME INHIBITION; LEUKEMIA CELL; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

ALKYNES; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; FURANS; FUSION PROTEINS, BCR-ABL; GAMMA-AMINOBUTYRIC ACID; HUMANS; LEUKEMIA, MYELOID, CHRONIC; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-FYN; PYRIMIDINES; SRC-FAMILY KINASES; TUMOR CELLS, CULTURED;

EID: 33847372943     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0307     Document Type: Article

References (30)

1. Goldman JM, Melo JV. Chronic myeloid leukemia - advances in biology and new approaches to treatment. N Engl J Med 2003;349:1451-63.
2. Kolb HJ, Schttenberg A, Goldman JM, et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood 1995;86:2041-50.
3. Talpaz M, Kantarajian H, Kurzrock R, et al. Interferon-α produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann Intern Med 1991;114:532-8.
4. Buchdungher E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylamino-pyrimidine derivative. Cancer Res 1996;56:100-4.
5. Druker BJ, Tamura S, Buchdungher E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996;2:561-6.
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-7.
7. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
8. Azam M, Latek RR, Daley GQ. Mechanism of autoinhibition and ST1571/ imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 2003;112:831-3.
9. Donato NJ, Wu JY, Stapley J, et al. BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to ST1571. Blood 2003;101:690-8.
10. Ren X, Cao C, Zhu L, et al. Lyn tyrosine kinase inhibits nuclear export of the p53 tumor suppressor. Cancer Biol Ther 2002;1:703-8.
11. Copland M, Hamilton A, Elrick LJ, et al. Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 2006;107:4532-9.
12. Savinov SN, Austin DJ. Diastereofacial solid phase synthesis and self-promoted cleavage of a [2.2.1] bicyclic diversity scaffold. Org Lett 2002; 4:4041-4.
13. Savinov SN, Austin DJ. Modular evolution of a chiral auxiliary for the 1,3-dipolar cycloaddition of isomunchnones with vinyl ethers. Org Lett 2002;4:1415-8.
14. Whitehouse DL, Nelson KH, Jr., Savinov SN, Lowe RS, Austin DJ. A metathetical cycloaddition-cycloreversion approach to the formation of furan scaffold libraries. Bioorg Med Chem 1998;6:1273-82.
15. Daley GQ, Baltimore D. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A 1988;85:9312-6.
16. Guo XY, Cuillerot JM, Wang T, et al. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells. Oncogene 1998;17:825-33.
17. Mahon FX, Deininger MWN, Schltheis B, et al. Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: diverse mechanism of resistance. Blood 2000;96:1070-9.
18. Mahon FX, Ripoche J, Pigeonnier V, et al. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction. Exp Hematol 1995;23:1606-11.
19. Nardi V, Azam M, Daley GQ. Mechanisms and implications of imatinib resistance mutations in Bcr-Abl. Curr Opin Hematol 2004;11:35-42.
20. Tokarski JS, Newitt J, Lee FY, et al. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistance ABL mutants. Cancer Res 2006;66:5790-7.
21. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 2004;305: 399-401.
22. + cells from CML patients in complete cytogenetic remission on imatinib mesylate treatment. Blood 2005;105:2093-8.
23. Talpaz M, Shah MP, Kantarjian H, et al. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N Engl J Med 2006;354: 2531-41.
24. Brugess MR, Skaggs BJ, Shah MP, Lee FY, Sawyers CL. Comparative analysis of two clinically active Bcr-Abl kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc Natl Acad Sci U S A 2005;102:3395-400.
25. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med 2006;354: 2542-51.
26. Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell 2005;7:129-41.
27. O'Hare T, Walters DK, Deiniger MWN, Druker BJ. AMN107: tightening the grip if imatinib. Cancer Cell 2005;7:117-9.
28. Gumireddy K, Baker SJ, Cosenza SC, et al. A non-ATP-competitive inhibitor orf BCR-ABL overrides imatinib resistance. Proc Natl Acad Sci U S A 2005;102:1992-7.
29. Wolff NC, Veach DR, Tong WP, Bornmann WG, Clarkson B, Ilaria RL, Jr. PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia. Blood 2005;105:3995-4003.
30. Yoshida K, Weichselbaum R, Kharbanda S, Kufe D. Role of Lyn tyrosine kinase as a regulator of stress-activated protein kinase activity in response to DNA damage. Mol Cell Biol 2000;20:5370-80.